Background: Spinal muscular atrophy (SMA) is a fatal motor neuron disease of childhood that is caused by mutations in the SMN1 gene. Currently, no effective treatment is available. One possible therapeutic approach is the use of antisense oligos (ASOs) to redirect the splicing of the paralogous gene SMN2, thus increasing functional SMN protein production. Various ASOs with different chemical properties are suitable for these applications, including a morpholino oligomer (MO) variant with a particularly excellent safety and efficacy profile.
INTRODUCTION
Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disease characterized by the degeneration of motor neurons in the spinal cord. 1 It results in progressive muscle weakness and atrophy Interestingly, this change in small nuclear RNA (snRNA) levels is cell type specific because the same snRNPs are not identically affected in all cell types. In addition to SMN1, the human genome harbors the paralogous gene SMN2, which essentially differs from SMN1 by a single C-to-T transition in exon 7 that modifies a splicing modulator and causes exon 7 exclusion in 90% of SMN2 mRNA transcripts. 9 The SMN protein lacking exon 7 does not oligomerize efficiently and is rapidly degraded, reducing SMN levels. The SMN2 gene also produces 10% full-length SMN protein, 9 which is a major modulator of SMA clinical phenotype. Patients with a lower SMN2 copy number have severe SMA (type I, infantile), whereas patients with higher SMN2 copy numbers have a milder form (types III-IV, juvenile or adult onset). 9 Currently, no effective therapies are available for SMA. Because SMA is caused by reduced SMN protein levels, most treatments have focused on increasing the amount of SMN, with strategies that include SMN2 transcription promotion with drugs or small molecules and SMN1 gene replacement using viral vectors carrying wild-type SMN1. 10 In transgenic mice with a severe SMA phenotype (SMAΔ7 mice), treatment with adenoassociated viral vectors encoding the human wild-type SMN protein results in phenotypic rescue with a log-fold increase in median survival (from weeks to more than a year). [11] [12] [13] [14] This result is quite remarkable because this animal model has previously invariably survived no more than 2 weeks and has historically been refractory to any therapeutic attempt. 10 An alternative promising molecular approach for SMA treatment is the modulation of SMN2 mRNA splicing to restore functional protein production. 15 Such an effect can be achieved with antisense oligos (ASOs), which are nucleotide acids analogs that can bind mRNA intronic and exonic sites and thus modify splicing events. 15 Numerous regions are involved in SMN2 splicing regulation, one of which is the negative intronic splicing silencer (ISS-N1), a 15-nucleotide splice-silencing motif located downstream of SMN2 exon 7. ASOs targeting the ISS-N1 region promote the inclusion of exon 7 without off-target effects. 16, 17 It has been hypothesized that hybridization of ASOs to the ISS-N1 region displaces transacting negative repressors and/or unwinds a cis-acting RNA stem-loop that interferes with the binding of U1 small nuclear RNA at the 5 0 splice site of exon 7. 16, 18 Preclinical and clinical studies have examined 2 types of ASO that differ in chemical structure for use in treating human diseases through mRNA regulation: (1) the 2'-O-methyl-modified phosphorothioate (2OMePS) oligonucleotides or the more stable variant 2 0 -O-(2-methoxyethyl)-modified (MOE) phosphorothioate oligonucleotides and (2) the morpholino oligomers (MOs). In the MO ASO, the phosphorothioate-ribose backbone is replaced with a phosphorodiamidatelinked morpholine backbone that is refractory to metabolic degradation. MOs feature low toxicity and have produced encouraging results in clinical trials, such as that for Duchenne muscular dystrophy. 15 In addition, impressive phenotype rescue has been observed in mouse models of SMA after ASOmediated SMN up-regulation in the central nervous system (CNS) using ASO-10-27 with MOE chemistry, 18 indicating promising potential as a treatment for SMA patients. The name ASO-10-27 is based on its position relative to the exon 7 donor site. Another recent work found the successful correction of SMN2 splicing with ASO-10-29 based on MO chemistry, with associated improvement of the SMA phenotype. 19 These findings suggest that ASO-induced interference with splicing will likely be one of the first molecular therapies for SMA to reach clinical development. Indeed, ASO from ISIS Pharmaceuticals (Carlsbad, California) is already in a Phase II trial. Given their excellent safety and efficacy profile, MOs are among the most promising candidates for this purpose. However, several critical issues remain to be resolved, including the optimal type of MO chemistry and sequence and the modality of administration. It is unclear whether local injection is sufficient to rescue SMA 19 or whether systemic injection is necessary and sufficient. 20 We have previously explored the use and optimization of MOs toward an effective clinical application, examining this strategy at the preclinical level in SMA animal models. We tested both unmodified MOs (bare MO) and octaguanidineconjugated MOs (Vivo-MOs), which include a group of guanidinium moieties that enables systemic administration and splicing modification in adult animals. 21 The optimal MO sequence is usually approximately 25 nt; longer sequences have been used for other applications (www.gene-tools.com), but they are more costly to manufacture.
In the present study, we investigated a 25-nt MO sequence targeting the ISS-N1(-10-34) region. We compared the efficacies of bare and Vivo-MOs and of using different combinations of local and systemic administration. We found the rescue of disease phenotype in SMA mice with combined systemic and local administration during the early disease phases. In our experiments, the 25-nt MO (both bare MO and Vivo-MO) was superior to the previously described MO-10-29 and ASO-10-27 sequences. [17] [18] [19] [20] Vivo-MO and bare MO molecules were equally effective at low doses; however, toxicity of Vivo-MO in neonatal mice limited its use at higher doses.
In the meantime and independently from our work, Zhou et al 22 performed experiments using a different mouse model ([SMN2] 2 þ/À ; smn À/À ) and also found that this 25-nt MO sequence was superior to other ASOs/MO sequences; however, their analyses were limited to survival and SMN expression data. Consistent with our observation, they also found that Vivo-MO is toxic in small pups. Furthermore, Mitrpant et al 23 confirmed that increased oligonucleotide length can enhance AO efficiency in promoting full-length SMN production. They designed and tested 14 different MOs of varying sizes (20, 22 , and 25 nt) near ISS-N1 (-10-25), and they identified the 25-nt sequence as being the most efficacious, both in vitro and in vivo, in the SMAΔ7 mouse model. With respect to their data, our present results not only confirmed that bare 25-nt MO is the best molecule but also proved that both systemic and local injections are necessary to rescue the disease phenotype in SMA. This finding was documented by phenotypic, neuropathologic, behavioral, motor function, and molecular tests. Moreover, we found that snRNA expression levels were deregulated in SMA mice and that MO treatment restored them. Overall, our presented strategy confirmed the excellent efficacy and therapeutic potential of MOs in SMA mice.
MATERIALS AND METHODS Morpholino Oligomers
The MO sequence was GTAAGATTCACTTTCA-TAATGCTGG, which was synthesized as bare MO or Vivo-MO (www.gene-tools.com). The Scr-MO sequence was GTAACATTGACTTTGATATTCCTGG, which was designed based on the best control sequence predicted using bioinformatic tool (www. gene-tools.com). MOs were dissolved in sterile saline solution at the appropriate concentration for injection ( Table 1) .
Animal Procedures
All transgenic animals were purchased from The Jackson Laboratory. All animal experiments were approved by the University of Milan and Italian Ministry of Health review boards in compliance with US National Institutes of Health guidelines. 24 Heterozygous breeding pairs (Smn þ/À , hSMN2
þ/þ ) were mated and genotyped as previously reported. 25 On the day of birth, SMA pups (Smn
) were cryoanesthetized and injected with 2 μL of MO at a predetermined concentration (Table 1) into the cerebral lateral ventricle, as previously described. 17, 19 Briefly, the pup was cryoanesthetized and hand-mounted over a backlight to visualize the intersection of the coronal and sagittal cranial sutures. A capillary needle with injection assembly was located 1 mm lateral and 1 mm posterior to the bregma and then inserted 1 mm deep to the skin edge ipsilateral lateral ventricle. 19 Regarding bare MO, 12 nM corresponds to 101.52 mg. Subcutaneous injections in postnatal days 0 and 3 (P0 and P3) pups were performed as previously described. 20 Western Blotting SMN protein levels were quantified by Western blotting, as previously reported. 20 
RNA Isolation and Quantitative Reverse Transcription-Polymerase Chain Reaction
Total RNA, including small RNAs, was isolated from tissues using the Absolutely RNA miRNA Kit (Agilent, Santa Clara, California): directly after collection of the tissues, the samples were lysed in the manufacturer's lysis buffer, homogenized using a micropestle and microtube, followed by phenol/chloroform extraction and subsequent column purification according to the manufacturer's protocol. When necessary, the eluates were additionally treated with Turbo-DNA-free (Invitrogen, Carlsbad, California) following the manufacturer's instructions. For mRNA analysis, 1 μg of total RNA was reverse transcribed in 50 μL of 1Â Affinity buffer containing 10 mM dithiothreitol, 0.4 mM deoxynucleotide triphosphates, 450 ng of random hexamers, 0.4 U/μL of RiboLock (Fermentas, Hamilton, Ontario, Canada), and 1 μL of AffinityScript reverse transcriptase (Agilent) according to the manufacturer's protocol. Reverse-transcribed material corresponding to 32 ng of RNA was amplified with MESA GREEN 
Analysis of Uridylate-Rich snRNAs
For snRNA analysis, 2 μg of total RNA, including small RNAs, was reverse transcribed at 371C in 50 μL of 1Â small RNA reverse transcription buffer (10 mM Tris, pH 8, 75 mM potassium, 10 mM dithiothreitol, 70 mM magnesium chloride, 0.8 mM anchored universal reverse transcription primer, 2 U/μL of RiboLock [Fermentas], 10 mM dNTPs, and 2.5 mM random ATP) supplemented with 5 U of Escherichia coli Poly (A) Polymerase (New England Biolabs, Ipswitch, Massachusetts) and 1 μL of AffinityScript reverse transcriptase (Agilent). Reactions were heat inactivated for 10 minutes at 851C. 27 Reverse-transcribed material corresponding to 18 ng of RNA was amplified with MESA GREEN qPCR Master Mix Plus for SYBR (Eurogentec) and the appropriate primers (600 nM each) in a total volume of 20 μL, using the RotorGene 6000 rotary analyzer (Corbett Life Science). 27 (the primer sequences are listed in Supplemental Table I in the online version at http://dx.doi.org/10.1016/j. clinthera.2014.02.004).
Immunohistochemistry
Spinal cords were harvested on P9 (n ¼ 6 animals), immersed in 4% paraformaldehyde solution and then in 20% sucrose in phosphate-buffered saline overnight, and frozen with liquid nitrogen. 19, 28 The tissues were cryosectioned and mounted on gelatinized glass slides. Tissue sections were stained with anti-human SMN KH antibody (diluted 1:10) overnight and then with Alexa Fluor 594 goat anti-rabbit IgG (Molecular Probes, Eugene, Oregon) (1:1000). Motor neurons were labeled with an antibody against mouse ChAT, as previously reported. 17 
Motor Neuron Counting
Motor neuron counting was performed as previously described. 17, 28 Serial cross-sections of the lumbar spinal cords were taken (12 μm thickness), and 1 of every 5 sections was processed. The number and size of all motor neurons determined in these cross-sections (n = 50 for each mouse) were quantified. We counted the cells in the spinal cord ventral horn that exhibited a fluorescent ChAT signal. To determine the mean number of motor neurons per spinal cord region for each animal, we analyzed approximately 10 levels of each spinal cord zone. Sections were taken from at least 100 μm apart to avoid double counting of the same cell. All the analyses were performed by masked investigators.
Myofiber Size
Quadriceps and intercostal skeletal muscles were fixed with paraffin and stained with hematoxylineosin to determine the myofiber cross-sectional size, as previously reported. 17, 28 Approximately 500 myofibers were randomly chosen, and the cross-sectional area of each myofiber was measured to determine the mean myofiber size. All the analyses were performed by masked investigators.
Analysis of Neuromuscular Junctions
Analysis of neuromuscular junctions (NMJs) in selected muscles was performed as previously described. 17, 28 Axons were identified by a rabbit polyclonal antibody for neurofilament medium or tubulin III (Millipore, Billerica, Massachusetts), whereas postsynaptic acetylcholine receptors were stained with Alexa 555-conjugated α-bungarotoxin (Molecular Probes). At least 100 NMJs from each muscle were randomly selected and evaluated to define the number of degenerated NMJs. All the analyses were performed by masked investigators.
Behavioral Tests
Each day, masked observers monitored all injected animals, as well as breeding pairs, for morbidity, mortality, and weight. Behavior was analyzed as previously reported. 19, 20, 24 The Rotarod test was performed using a 4-phase profile 20 : phase 1, from 1 to 10 rpm in 7.5 seconds; phase 2, from 10 to 0 rpm in 7.5 seconds; phase 3, from 0 to 10 rpm in 7.5 seconds in the opposite direction; and phase 4, from 10 to 0 rpm in 7.5 seconds. Hind-limb suspension tests evaluate the positioning of the legs and tail. Mice are suspended by their hind limbs from the lip of a standard 50-mL plastic centrifuge tube. The posture will be scored according to these criteria: score of 4 denotes normal hind-limb separation with tail raised; score of 3, weakness is evident and hind limbs are closer together but seldom touch each other; score of 2, hind limbs are Clinical Therapeutics close to each other and often touching; score of 1, weakness is apparent and hind limbs are almost always in a clasp position with the tail raised; and score of 0, constant clasping of the hind limbs with the tail lowered. Grip-strength and righting reflex tests were performed as previously described. 29 
Statistical Analysis
Data are expressed as mean (SE). Statistical analyses were performed using 1-way ANOVA and Bonferroni multiple post hoc comparisons. 28 The Kaplan-Meier survival curve was analyzed using the log-rank test equivalent to the Mantel-Cox test. 24 All statistical analyses were performed using Stats direct software.
24
P o.05 was considered statistically significant. For uridylate-rich snRNA (UsnRNA) analysis, both 1-sided and unpaired t tests were performed. 27 
RESULTS

Systemic and Intrathecal Delivery of Bare and Vivo-MO Dose Dependently Rescues Transgenic Mice With Severe SMA
We designed a 25-nt MO sequence (HSMN2Ex7D [-10-34] ) to target the ISS-N1 region in the SMN2 gene based on the best bioinformatically predicted MO sequence. 30 We named this sequence MO-10-34 based on its position relative to the exon 7 donor site ( Figure 1A ). We synthesized both bare MO and octaguanidine-conjugated MO (Vivo-MO). We also produced a nonspecific MO with a scrambled (Scr) sequence for each MO oligomer. To determine the effectiveness of MO-10-34, we investigated different administration protocols in SMA transgenic mice that mimic type 1 severe SMA (SMA Smn À/À , hSMN2
; called SMAΔ7 mice). Intracerebroventricular (ICV) injection of MO-10-34 bare MO and Vivo-MO on P0( Figure 1C) or subcutaneous (SC) injection on P0 and P3 (1 dose per day) ( Figure 1D ) (n ¼ 43 per group) was performed using a starting dose of 2 nM, in line with previous reports, 19, 20 and increasing to 24 nM. Treatment conditions and the treated SMA animal groups are described in detail in Table I . Under these conditions, we observed a significant survival increase in mice treated with bare MO or Vivo-MO using either delivery route compared with untreated and Scr-treated SMA mice. The maximum survival (72 days) was obtained with 24 nM bare MO injected ICV, which was significantly higher than that in Scr-treated mice (16 days; P o 0.001). However, we observed severe toxic effects for this dose, with only 2 of 10 mice surviving after the injection.
Although the observed 42-fold extension of survival was promising, it was slightly inferior to that previously reported with similar strategies. Data are controversial regarding whether SMN rescue mediated by oligonucleotide strategies necessitates intra-CNS administration, as favored by Porensky et al, 19 or systemic administration, as emphasized by Krainer et al. 20 On the basis of these considerations, we performed combined administration (ICV and SC) and increased the treatment dose. We observed dosedependent toxicity of Vivo-MO in neonatal mice, which was in agreement with data reported by the manufacturer (Gene Tools, Philomath, Oregon) and by other groups 22 regarding local injection in young mice. This toxicity limited the possibility of further increasing the Vivo-MO dose. Injections of more than 2 nM of Vivo-MO resulted in high mortality (450%, data not shown). Therefore, we used a range of bare MO doses (2-12 nM) and limited the Vivo-MO dose to 2 nM (Table I) .
Control heterozygous mice (Smn
) that received ICV and SC MO-10-34 injections exhibited normal survival and behavior. SMAΔ7 mice that were untreated or injected ICV and/or SC with Scr-MO exhibited a mean survival time of 13 or 17 days, respectively ( Figure 1B, 1C, and  1D ). In comparison, combined ICV and SC injection of bare MO led to significant dose-dependent survival increases in SMAΔ7 mice: 2 nM, 34 days; 5 nM, 62 days; and 10 nM, 86 days (n ¼ 43 per group; P o 0.001 vs Scr; Figure 1D ). The maximum survival of 183 days was achieved with 10 nM bare MO. Remarkably, some of mice treated with the highest dose (12 nM) of bare MO are still alive and present complete phenotypic rescue, indicating an efficacy comparable with gene therapy ( Figure 1B) . The median survival obtained with 12 nM is 120 days.
Head-to-head comparison of bare MO with Vivo-MO at the same dose revealed that they were substantially equivalent regarding survival. Importantly, in our hands, 25-nt MO was superior to the previously reported MO-10-29 19 and ASO-10-27 20 sequences (see Supplemental Figure 1 in the online version at http://dx.doi.org/10.1016/j.clinthera.2014.02.004) as described by Zhou et al 22 and Mitrpant et al. 23 We also found that combined treatment in symptomatic mice on P5 and P7 significantly increased survival, albeit less than early treatment (see Supplemental Figure 1 in the online version at http://dx.doi.org/10.1016/j.clinthera. 2014.02.004). This result emphasized the importance of early treatment, although protocol optimization might further improve the results after later treatment. Treated SMA mice exhibited a dose-dependent size variation from runts to mice that were comparable to their heterozygous littermates. Starting at 2 months of age, we started to detect minimal necrosis signs in the tail and ears, as well as ocular problems that were previously described as systemic signs of the SMN defect. 19, 20 However, animals treated with combined ICV and SC administration of higher doses could run and climb normally (see Supplemental Movie 1 in the online version at http://dx. doi.org/10.1016/j.clinthera.2014.02.004) and reached nearly the same appearance as heterozygous and wildtype mice, which was profoundly different from that of the Scr-treated controls that died at 2 weeks.
Effect of MO-10-34 on Exon 7 Inclusion and SMN Levels in the SMA CNS and Other Organs
To examine the molecular effect of MO on SMN levels, we subjected SMAΔ7 mice to ICV (P0) and SC (P0-P3) injection of bare MO (12 nM). MO-and Scrtreated SMA mice (n ¼ 5 per group) were humanely (Figure 2A and 2B) . These results were confirmed by quantitative reverse transcription-polymerase chain reaction of full-length human SMN2 and total SMN2 mRNA levels (n ¼ 3 per group). Relative to Scr-treated mice, this ratio was significantly increased after MO treatment in spinal cord (8.42-fold; P ¼ 0.0003), liver (17.82-fold, P ¼ 0.0001), and brain (11.35-fold, P ¼ 0.015) ( Figure 2E ) at P7. At P20, the splicing correction in the brain (1.84-fold, P ¼ 0.0054) was 4.5-fold less efficient than at P7, whereas the splicing correction in the spinal cord at P20 (8.21-fold, P ¼ 0.045) was comparable to that at P7 ( Figure 2F ). We also compared the efficiencies of splicing correction on combined 12 nM ICV and 12 nM SC vs 24 nM SC injections. The subcutaneous injection is only 2.29-fold less efficient in the brain (P ¼ 0.026) and 3.26-fold less efficient in the spinal cord (P ¼ 0.048) (see Supplemental Figure 3 in the online version at http:// dx.doi.org/10.1016/j.clinthera.2014.02.004).
Deregulation of UsnRNA Levels in SMA7 Mice and Reduction of Deregulation by MO Treatment
Using quantitative reverse transcription-polymerase chain reaction, we investigated whether U1, U2, U4, U5, U6, U11, U12, and U4atac snRNA levels were deregulated in various tissues of SMAΔ7 mice and whether these levels were restored after MO treatment. In accordance with previous reports in other mouse models, 8 SMAΔ7 mice exhibited tissue-and snRNP-specific deregulation of all investigated UsnRNAs, except U1. We observed significantly reduced U4atac snRNA levels (by 42-fold) in the spinal cords of SMA mice treated with Scr-MO compared with heterozygous mice (P ¼ 0.00782; Figure 3) . Levels of the other deregulated UsnRNAs were also decreased in the spinal cords of SMA mice, except U6, which was increased. MO treatment restored the levels of all of the deregulated snRNAs to normal, including the increase of U6 snRNA (U2 snRNA P ¼ 0.0034, U4 snRNA P ¼ 0.0049, U5
snRNA P ¼ 0.0029, U11 snRNA P ¼ 0.0067, U12 snRNA P ¼ 0.0087, U4atac snRNA P ¼ 0.0047, and U6 snRNA P ¼ 0.0321) (Figure 3 ). In the brains of Scrtreated SMA mice, we observed up-regulated U6 snRNA levels (P ¼ 0.02739) and reductions of U4 (P¼ 0.04171) and U4atac (P ¼ 0.00069) snRNA levels. MO treatment only slightly restored the deregulated snRNA levels in the brain (U2 P ¼ 0.08581, U6 P ¼ 0.06910, and U4atac P ¼ 0.05252) (see Supplementary Figure 4 in the online version at http://dx.doi.org/10.1016/j.clinthera.2014.02.004). In the liver, we observed downregulation of U4 (P ¼ 0.07705) and U4atac (P ¼ 0.00685), and the levels of U4 snRNA in the liver were fully restored by MO treatment (P ¼ 0.00089; see Supplementary Figure 4 in the online version at http:// dx.doi.org/10.1016/j.clinthera.2014.02.004).
Effect of MO on Motor Neuron Cell Number in the Spinal Cord and Muscle Trophism in Treated SMA Mice
To determine the efficacy of MO treatment regarding improvement of the neuropathologic phenotype, we analyzed SMAΔ7 mice treated with 12 nM bare MO by both ICV and SC compared with Scr-treated mice. We investigated spinal cord motor neuron cell counts and muscle morphology parameters in P9 mice (n ¼ 5 per group). Histologic examination revealed striking improvements in MO-treated mice. The number of motor neurons per spinal cord in MO-treated mice was comparable to that in control heterozygous littermates and was significantly higher than in untreated animals (P o 0.001; see Supplemental Figure 5 in the online version at http://dx.doi.org/10.1016/j. clinthera.2014.02.004). Staining of the NMJs with α-bungarotoxin revealed that NMJ architecture in treated mice was similar to that of their heterozygous littermates, and the mean NMJ diameter was significantly increased in treated compared with untreated SMAΔ7 mice (P o 0.001; Figure 4 ). MO injection resulted in statistically significant increases in muscle growth, evaluated by quantification of the mean myofiber cross-sectional area for each group (MOtreated vs Scr-treated mice, P o 0.001; Figure 5 ). The heart weight of MO-treated mice was also similar to that of their heterozygous littermates and was significantly increased compared with in untreated SMAΔ7 animals (see Supplemental Figure 6 in the online version at http://dx.doi.org/10.1016/j.clinthera.2014. 02.004). 
Effect of MO on Neuromuscular Function in SMA Mice
In proportion to the amelioration observed in motor neuron count and muscle physiology, most of the mice that were treated with the combined ICV and SC injections of higher MO doses exhibited no overt signs of motor dysfunction and were almost indistinguishable from their heterozygous littermates (see Supplemental Movie 1 in the online version at http://dx.doi.org/10.1016/j.clinthera.2014.02.004; Figure 6 ). We used different tests to evaluate behavior and motor function during the first weeks of life (when Scr-treated mice were still alive) and during adulthood. In the early stages, we evaluated the mice using the righting test, test tube score, hand grip test, and weight. In each test, treated animals dose dependently performed significantly better than untreated and Scr-treated SMA mice (P o 0.001 vs Scrtreated mice).
At 3 months of age, mice were subjected to the Rotarod test, which requires limb muscle strength, balance, and coordination. Three-month-old MOtreated SMA mice were able to stay on the rotating rod for the same amount of time as control Because SMA is a neuromuscular disease, this performance is remarkable proof of phenotypic amelioration. At this stage, the treated SMA mice were able to walk, explore the environment, and perform various behaviors similarly to control heterozygous mice ( Figure 6 ). Overall, these results combined with the above-presented survival data support a complete rescue of SMA phenotype in this animal model treated with the combined injections.
DISCUSSION
Modulating RNA splicing to restore functional protein production is one of the most promising therapeutic options to treat neuromuscular diseases, including SMA. Because SMN2 can produce a small amount of full-length SMN protein by alternative splicing, one possible strategy is to target SMN2 to increase SMN production in patients with SMA. Recent developments in ASO technology include 2OMePS and the MOE variant. MOs have produced encouraging results in animal models of neuromuscular disorders and more recently in clinical trials, including the targeted skipping of exon 51 in Duchenne muscular dystrophy. 15 This technology has made it possible for us and others to restore SMN expression in SMA mice, in many cases achieving complete phenotype rescue. 17, 19, 20, 22, 23 Both phosphorothioate ASO and MO chemistries are promising for treating neuromuscular diseases, but bare MO has been found to be superior to 2OMePS molecules in some experimental models (particularly in Duchenne muscular dystrophy animal models) because of its stability and efficacy in targeting mRNA 15 and its excellent safety profile. It was previously reported that 2OMe-based ASOs did not perform adequately in vivo in SMA animals, 31 whereas MOE chemistry was active and well tolerated, with impressive results in SMA mice. 20 Our current results confirm and extend the previous data indicating the excellent efficacy of MO in redirecting SMN2 splicing and thus improving the SMA disease phenotype at the molecular, cellular, and functional levels in a mouse model of severe SMA type 1 disease.
In agreement with previous studies, we found that combined subcutaneous and local injection of bare MO and Vivo-MO successfully modified SMN2 splicing, resulting in robust expression of SMN mRNA and protein. In turn, this SMN up-regulation correlated with increased numbers of motor neurons, amelioration of NMJ architecture, and improved muscle trophism, which led to impressive therapeutic effects in SMA mice in terms of survival and neuromuscular function. The phenotype of some SMA animals treated with the higher dose was almost indistinguishable from their heterozygous littermates.
The successful translation of this strategy into clinical use will rely on the continued optimization of this approach, which was one goal of our work. Some critical points in the development of this technique include the design of the best MO oligomer sequence and the investigations of various chemical modifications. We evaluated a 25-nt sequence that was predicted to be the best sequence by an algorithm from Gene Tools. We found that it indicated a higher efficacy than was previously described for ASO-10-27 and ASO-10-29 synthesized with MO chemistry, 17, 19, 20 as was also found by the groups of Zhou et al 22 and Mitrpant et al. 23 We cannot directly compare ASO-10-27 synthesized as MOE with our MO-10-34 sequence because of the patent on MOE chemistry (ISIS Pharmaceuticals). Overall, our data confirm the critical importance of targeting the ISS-N1 region for effective modulation of SMN2 splicing and emphasize that small variations in the ASO sequences used can be important.
Regarding the chemical modification of oligomers, we tested Vivo-MO molecules that have a terminal octaguanidinium dendrimer to enhance cell permeability. Vivo-MOs have been previously described as superior to nonconjugated MO for achieving mRNA targeting after intravenous administration in animals. 21 We found that Vivo-MO improved the SMA phenotype equally to, but not better than, bare MO. One possible explanation for this finding is that MOs were administered in neonatal mice, which have more permeable tissues and cells, allowing the bare MO to more easily enter the cytoplasm. Furthermore, as previously described by the manufacturer (Gene Tools), we found that neonatal mice did not tolerate high doses of Vivo-MO, and we were thus unable to further increase the dose. The described toxicity was also in accordance with the findings of Zhou et al. 22 Although administration of Vivo-MO may be more advantageous than bare MO during the symptomatic phase, this potential benefit could not be entirely appreciated because it is more difficult to modify disease progression at this stage. It would be interesting in future studies to evaluate local injection of bare MO in conjunction with systemic administration of Vivo-MO in presymptomatic and symptomatic phases. Remarkably, we observed significant phenotypic amelioration during symptomatic phases, which warrants additional investigation with alternative protocols. Addressing the disease after its onset is a present challenge in SMA research. For this purpose, it will be necessary to better understand the pathogenetic mechanisms responsible for disease progression even when SMN expression is restored. We hypothesize that the best therapy will be a combination of molecular therapies that address SMN level in addition to other later pathogenetic events.
The tested the combinatory strategy but only in a small subset of experiments. Hua et al 20 found that a combined injection protocol resulted in a major improvement of median survival compared with ICV alone, but their best results were obtained with a SC injection at a high dose. Porensky et al 19 also used the combinatory administration and found that it produced an impressive survival advantage that was equivalent to, but not greater than, high-dose MO injected ICV at P0. In addition, our data indicate that the combined regimen at the maximal tested dose was more efficacious compared with use of a single route, even if the combined administration yielded the same survival rate as reported previously for ICV administration alone. We produced a new set of data that allow for better comparison between ICV and SC single-route administration compared with combinatorial administration at higher doses. The highest dose injected only SC resulted in a modest survival increase to a mean of 28.8 days, with 2 mice remaining alive at 32 days, which was much lower than the survival achieved with the combined injection of the same dose. For ICV administration of the same dose, we observed severe toxic effects, and the mice that were not killed by the injection exhibited shorter survival than did all of the mice treated with combined injections. This adverse effect was not linked to a problem associated with the volume of the injection but to the high dose given in a single administration. For example, Porensky et al injected 135 mg of ICV MO per injection at P0, P1, and P2 for a total of 405 mg with no signs of toxic effects.
An analysis of SMN2 splicing modulation achieved by the same dose (24 nM) using different administration regimens revealed that splicing in the CNS was less effective with SC injection only than with the combined administration protocol (12 nM ICV and 12 nM SC), suggesting that the systemic injection of MO results in limited diffusion in the CNS and likely has a therapeutic effect on the peripheral organs (see Supplemental Figure 3 in the online version at http:// dx.doi.org/10.1016/j.clinthera.2014.02.004), even if the blood brain barrier is partially open for MO when the injections are given. These findings support the hypothesis that the peripheral actions of MO may have a role in phenotype rescue because the full phenotype rescue could not be entirely accounted for by CNS action alone. Overall, at the maximal tested dose, the combined regimen was the most efficacious method. We believe that our findings provide a new, more balanced perspective regarding the antisense effect on SMA rescue. SMN deficiency affects snRNPs in a tissue-and subset-specific manner. 8, 32 The snRNPs that are most affected by SMN depletion are the so-called minor snRNPs that constitute the minor spliceosome. Although most introns in pre-mRNAs are processed by the major spliceosome (composed of U1, U2, U4/ U6, and U5 snRNPs), approximately 1% of introns require the activity of the minor spliceosome (composed of U11, U12, U4atac/U6atac, and U5 snRNPs). 33, 34 Importantly, several genes required for motor circuit function are dependent on the minor spliceosome for proper pre-mRNA splicing. 35 We observed that almost all of the analyzed snRNAs were deregulated in SMA mice, with the minor snRNA U4atac being most affected by SMN deficiency in all tissues, along with its major spliceosome counterpart U4. Importantly, MO treatment of SMAΔ7 mice fully restored snRNA levels in the spinal cord to those present in healthy heterozygous mice. This analysis provides deeper insights into the pathogenetic mechanism. It will be of great interest to study the dose-dependent effects of MO on the restoration of the individual snRNA levels and to validate whether the detection of snRNAs levels in peripheral blood can be used as a diagnostic marker and for therapy assessment. The remarkable and reproducible efficacy of MO regarding life extension, gains of weight and strength, and neuropathologic feature improvement is comparable to that obtained with gene therapy. MOs have a notably excellent safety profile, which has already been tested in clinical trials. Importantly, the gene stays expressed under its own endogenous promoter, subjected to its regular turnover, thus obviating the need for transgene introduction. Disadvantages of ASO therapy for SMA include the likelihood of relatively invasive repeat CNS dosing; however, this disadvantage can be overcome with the aid of the electronic pump that is already used to administer the drug intrathecally in the clinic. 36, 37 Indeed, we believe that systemic administration must be associated with local delivery. Ideally, if the chemical modification of ASOs or their conjugation with peptide will allow efficient crossing of the blood brain barrier, then systemic noninvasive administration will likely be the better option. For instance, it has been previously reported that 9 arginine tags fused to rabies virus glycoprotein peptides can deliver antisense oligonucleotides across the blood brain barrier. 38 Overall, in the present study, we achieved our primary objectives of correcting SMA phenotypes in mice using MO and expanding the knowledge of the field regarding selection of the best oligomer sequence, MO chemistry, dose-response effect, and route of administration. Future studies are needed to pursue continued improvement of the administration protocol (time, dose, and route of administration) and should include tests in other larger animal models to confirm the data obtained in mice and to progress toward future clinical trials. MO has the potential to ameliorate the natural history of SMA and requires further evaluation in clinical safety and efficacy profile trials. 
